News and Press Releases
SeaBeLife secures €2 million
This funding will help fast-track the launch of clinical trials in dry AMD and severe acute hepatitis programs 1 October 2025 -- Roscoff, France -- SeaBeLife, a biotechnology company developing...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 1, 2025
PACE launches its third funding round today, supporting innovative projects that tackle resistant bacterial infections posing the greatest threat to global health
1 October 2025 -- Alderley Park, UK -- To stay ahead of the escalating antibiotic resistance crisis, we need bold thinking and transformative innovation. According to the World Health Organization...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 1, 2025
Bioxodes secures new funds to reach early 2025 milestones and pursue Series B financing
Bioxodes raises €2.7 million from existing investors in Series A extension Interim data from BIRCH intracerebral hemorrhage (ICH) Phase 2a trial in Q1 2025 Recruitment of up to 16 additional...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 12, 2025
AbbVie’s SKYRIZI® (risankizumab) Accepted by the Scottish Medicines Consortium for Adults with Moderately to Severely Active Ulcerative Colitis
Risankizumab will be available on the NHS in Scotland for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to,...
Category: Clinical Trials, Pharmaceutical
Posted: January 13, 2025
Capsida Announces AbbVie Opt-in for First Genetic Medicine Program from Neurodegenerative Disease Collaboration
Capsida to receive a $40 million license payment and is eligible for additional milestones and royalties 7 January 2025 -- California, US -- Capsida Biotherapeutics today announced that AbbVie has...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 7, 2025
ENEA-Tech Biomedical Foundation Invests €6m in BetaGlue® Therapeutics
Brings 2024 Funding Round Total to €24m 16 December 2024 -- Milan, Italy -- BetaGlue Therapeutics S.p.A, an Italian clinical-stage oncology company developing an innovative radiotherapy platform for the targeted...
Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: December 16, 2024
BetaGlue Therapeutics SpA. Piazzetta Umberto Giordano 4, 20122 Milan, Italy
Deep Science Ventures and General Inception collaborate to create fibrosis-focused therapeutics company
12 December 2024 – London, UK, and Palo Alto, CA, US – Deep Science Ventures, a UK-based venture studio, and General Inception, a US-based venture studio, today announced a collaboration...
Category: Drug Discovery, Other
Posted: December 12, 2024
Discover the Power of AI in Biopharma: TVM to host thought-provoking sessions at BIO-Europe 2024
30 October 2024 – Munich, Germany and Montreal, Quebec, Canada – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today...
Category:
Posted: October 31, 2024
TVM Capital GmbH, TVM Life Science Management GmbH, Ottostraße 4, 80333 Munich, Germany
Antiverse raises £3.5M ($4.6M) to advance generative AI antibody design platform
Increases total equity financing raised to £7.2M ($10.1M) New facilities in Boston and Prague will provide increased capacity to deliver pipeline of pharma and biotech projects Funding to progress internal...
Category: Biotechnology, Drug Discovery
Posted: October 17, 2024
Nxera Pharma Receives US$10m from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone
27 June 2024, Tokyo, Japan and Cambridge, UK - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565), announces that it has reached an important R&D milestone under its multi-target discovery collaboration...
Category: BioManufacturing, Other, Pharmaceutical
Posted: June 28, 2024
Oxford Drug Design and CRUK Scotland Institute awarded MRC grant funding to advance novel cancer therapeutics discovery
Collaboration to use genetically engineered mouse models to validate a new approach to cancer therapy 4 June 2024 - United Kingdom - The CRUK (Cancer Research UK) Scotland Institute and Oxford...
Category: Drug Discovery
Posted: June 10, 2024
Oxford Drug Design Lt,d Oxford Centre for Innovation, New Road, Oxford, OX1 1BY, UK
Owlstone Medical Secures $6.5m to Support Development of Breath-based Diagnostics for Infectious Disease
$5m equity investment and initial $1.5m grant funding committed by the Bill & Melinda Gates Foundation for development of breath-based diagnostic solutions to improve outcomes in the developing world Funding...
Category: Biotechnology, Other
Posted: April 25, 2024
Owlstone Ltd, 127 Cambridge Science Park, Milton Road, Cambridge, CB4 0GD, UK
Eisbach and Cancer Focus Fund Announce $4.5m Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumours
Eisbach is enabling the potential of synthetic lethality by developing novel compounds to exploit molecular vulnerabilities uniquely present in many hard-to-treat cancers 21 March 2024 -- Martinsried, Germany and Texas, US...
Category: Biotechnology, Pharmaceutical
Posted: March 21, 2024
Calluna Pharma launches and announces €75m Series A financing to develop novel therapies for inflammatory and fibrotic diseases
Clinical stage company formed from the merger of Oxitope Pharma and Arxx Therapeutics Calluna Pharma has a pipeline of selective antibodies targeting immunological diseases New company to complete multiple clinical...
Category: Drug Discovery, Pharmaceutical
Posted: January 23, 2024
Orakl Oncology raises €3 million to develop its techbio platform forprecision oncology
4 October 2023 -- Paris, France -- Orakl Oncology, a precision oncologystart-up, today announces that it has raised €3m to develop its techbio platform thatintegrates best-in-class biology with real-world patient...
Category: Biotechnology
Posted: October 9, 2023
